Advertisement
Advertisement
U.S. Markets close in 2 hrs 5 mins
Advertisement
Advertisement
Advertisement
Advertisement

Translate Bio, Inc. (TBIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
37.360.00 (0.00%)
As of 4:00PM EDT. Market open.
Advertisement

Translate Bio, Inc.

29 Hartwell Avenue
Lexington, MA 02421
United States
617 945 7361
http://www.translate.bio

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees122

Key Executives

NameTitlePayExercisedYear Born
Mr. Ronald C. Renaud Jr.CEO & Director885.47k488.19k1969
Mr. Paul D. Burgess J.D.Chief Legal Officer, COO & Sec.596.55kN/A1974
Dr. Richard WoosterChief Scientific Officer596.55kN/A1965
Dr. Ann Barbier M.D., Ph.D.Chief Medical Officer610.55kN/A1964
Dr. E. Rand SutherlandPresN/AN/AN/A
Mr. Brendan Smith M.B.A.CFO, Corp. Strategy & Principal Financial OfficerN/AN/A1976
Mr. Robert D. PrentissVP, Corp. Controller, Treasurer & Interim Principal Accounting OfficerN/AN/A1972
Mr. Frank DeRosaChief Technology OfficerN/AN/AN/A
Ms. Teri Babine DahlmanVP of Corp. Communications & Investor RelationsN/AN/AN/A
Ms. Paula A. CloghessyChief People OfficerN/AN/A1971
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. has a collaboration and license agreement with Sanofi Pasteur Inc. The company was founded in 2011 and is headquartered in Lexington, Massachusetts.

Corporate Governance

Translate Bio, Inc.’s ISS Governance QualityScore as of June 30, 2021 is 8. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 9; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement